SCHEMBL20554136

SCHEMBL20554136

C=CC(=O)Nc1ccnc(Oc2ccc(Cl)cc2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K7 O14733 2/20 0.54
TGM2 P21980 2/20 0.48
BTK Q06187 7/20 0.47
EGFR P00533 7/20 0.47
GRM5 P41594 1/20 0.47
BRD4 O60885 1/20 0.46
ERBB2 P04626 2/20 0.43
TEC P42680 1/20 0.43
TXK P42681 1/20 0.43
BLK P51451 1/20 0.43
BMX P51813 1/20 0.43
JAK3 P52333 1/20 0.43
ERBB4 Q15303 1/20 0.43
MAPK3 P27361 1/20 0.42
KDR P35968 1/20 0.41
SCN9A Q15858 1/20 0.41
MEN1 O00255 1/20 0.41
LMNA P02545 1/20 0.41
RECQL P46063 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30132615 1.00 MAP2K7 (0.54) MAP2K7TGM2BTKEGFRGRM5
SCHEMBL20554486 0.81 EGFR (0.51) MAP2K7TGM2BTKEGFRGRM5
SCHEMBL30132598 0.81 EGFR (0.51) MAP2K7TGM2BTKEGFRGRM5
SCHEMBL22732028 0.80 TGM2 (0.62) MAP2K7TGM2BTKEGFRBRD4
SCHEMBL30132606 0.80 MAP2K7 (0.49) MAP2K7TGM2BTKEGFRBRD4
SCHEMBL20554426 0.80 MAP2K7 (0.49) MAP2K7TGM2BTKEGFRBRD4
SCHEMBL20456243 0.79 TGM2 (0.73) MAP2K7TGM2BRD4MEN1LMNA
SCHEMBL23899138 0.77 MAP2K7 (0.59) MAP2K7BTKEGFR
SCHEMBL16665293 0.76 MAPK10 (0.52) MAP2K7BTKEGFRGRM5ERBB2
SCHEMBL20554319 0.75 TGM2 (0.52) MAP2K7TGM2BTKEGFRGRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110770211-B Alpha, beta unsaturated amide compound 协和麒麟株式会社 2023-09-19 CN disclosed
CN-108430972-B Alpha, beta-unsaturated amide compound 协和麒麟株式会社 2022-12-27 CN disclosed
US-11447471-B2 α,β-unsaturated amide compound KYOWA KIRIN CO., LTD. (JP) 2022-09-20 US disclosed
US-11332455-B2 α,β-unsaturated amide compound KYOWA KIRIN CO., LTD. (JP) 2022-05-17 US disclosed
US-20210380551-A1 ALPHA,BETA-UNSATURATED AMIDE COMPOUND KYOWA KIRIN CO., LTD. (JP) 2021-12-09 US disclosed
US-20210155612-A1 Alpha,Beta-UNSATURATED AMIDE COMPOUND KYOWA KIRIN CO., LTD. (JP) 2021-05-27 US disclosed
US-10787428-B2 α,β-unsaturated amide compound KYOWA KIRIN CO., LTD. (JP) 2020-09-29 US disclosed
EP-3712129-A1 ALPHA, BETA-UNSATURATED AMIDE COMPOUND Kyowa Kirin Co., Ltd. (JP) 2020-09-23 EP disclosed
CN-110770211-A α unsaturated amide compound 协和麒麟株式会社 2020-02-07 CN disclosed
US-20190010136-A1 ALPHA,BETA-UNSATURATED AMIDE COMPOUND KYOWA HAKKO KIRIN CO., LTD. (JP) 2019-01-10 US disclosed
EP-3401309-A1 a, ß UNSATURATED AMIDE COMPOUND Kyowa Hakko Kirin Co., Ltd. (JP) 2018-11-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210155612-A1 Alpha,Beta-UNSATURATED AMIDE COMPOUND NR1H2, NR1H3, RXRA MAP2K7 4651/4885TGM2 2323/4885BTK 2944/4885
US-11447471-B2 α,β-unsaturated amide compound NR1H2, RXRA, RXRB MAP2K7 4617/4885TGM2 2474/4885BTK 2864/4885
US-10787428-B2 α,β-unsaturated amide compound NR1H2, NCOA1, NR0B1 MAP2K7 4615/4885TGM2 2608/4885BTK 2983/4885
US-20210380551-A1 ALPHA,BETA-UNSATURATED AMIDE COMPOUND NR1H2, NR1H3, NCOA1 MAP2K7 4672/4885TGM2 2448/4885BTK 3118/4885
US-11332455-B2 α,β-unsaturated amide compound NR1H2, NCOA1, NR0B1 MAP2K7 4615/4885TGM2 2608/4885BTK 2983/4885
US-20190010136-A1 ALPHA,BETA-UNSATURATED AMIDE COMPOUND NR1H2, NR1H3, NCOA1 MAP2K7 4672/4885TGM2 2448/4885BTK 3118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.